# Impact of Molecular Subtypes in Muscle-invasive Bladder Cancer on Predicting Response and Survival after Neoadjuvant Chemotherapy

Source: https://onco.cc/key-papers/paper-seiler-bladder-molecular-subtypes-chemotherapy-eur-urol-2017/  
OnCo record `paper-seiler-bladder-molecular-subtypes-chemotherapy-eur-urol-2017` (Key paper). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A study that sorted muscle-invasive bladder cancers into molecular types from gene activity and found that the basal type gained most from chemotherapy before surgery.

## Summary

A single-sample genomic subtyping classifier predicted four consensus molecular subtypes with 73 per cent accuracy, and patients with basal tumours showed the most improvement in overall survival with neoadjuvant chemotherapy.

## Fields

- Kind: Key paper
- Last checked: 2026-11-04
- Journal: European Urology
- Year: 2017
- DOI: 10.1016/j.eururo.2017.03.030
- Authors: Seiler R, Ashab HAD, Erho N, et al.
- Findings: Subtype classifier accuracy 73%.; Basal tumours: most overall survival improvement with neoadjuvant chemotherapy.
- What it means: Molecular type may help choose who benefits most from chemotherapy before bladder removal.
- Caveats: Retrospective; the abstract does not name the commercial product.

## Sources

- Seiler et al., Eur Urol 2017: https://doi.org/10.1016/j.eururo.2017.03.030
- PubMed: https://pubmed.ncbi.nlm.nih.gov/28390739/

## Connected records

- cancers: [Muscle-invasive and advanced bladder cancer](https://onco.cc/cancers/muscle-invasive-bladder-cancer/)
- fronts: [Diagnostics & Biomarkers](https://onco.cc/fronts/diagnostics/)
- technologies: [Gene-expression prognostic assays](https://onco.cc/technologies/gene-expression-prognostic-assays/)
- drugs: [Decipher Bladder](https://onco.cc/drugs/decipher-bladder/)
- terms: [Biomarker](https://onco.cc/terms/biomarker/)

---
JSON: https://onco.cc/api/v1/entities/paper-seiler-bladder-molecular-subtypes-chemotherapy-eur-urol-2017.json